See Supplemental Patient Information
- Exercise caution in patients with clinically significant bladder outflow obstruction and in patients with gastrointestinal obstructive disorders because of the risk of urinary retention and gastric retention
- Oxybutynin may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony, and myasthenia gravis
- CNS anticholinergic effects such as headache, dizziness, and somnolence have been reported in patients treated with products containing oxybutynin. Closely monitor signs of anticholinergic CNS effects after initiating treatment with oxybutynin
- Cases of angioedema indicating hospitalization and emergency medical treatment have been reported following oral oxybutynin use. In the event of angioedema, discontinue oxybutynin-containing products and institute appropriate therapy
- Discontinue therapy in patients who develop skin hypersensitivity to oxybutynin
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Gastroesophageal reflux
- Cardiovascular disease
- Hypertension
- Hyperthyroidism
- Prostatic hypertrophy
- Autonomic neuropathy
- Concomitant use with drugs (e.g., bisphosphonates) that may cause/exacerbate esophagitis
- Use of anticholinergic
- High environmental temperature
- Elderly patients
Supplemental Patient Information
- Advise patients to avoid exposure of the patch to sunlight; hence, cover the application site with clothing
- Inform patients to avoid alcohol during therapy, as it may further potentiate drowsiness caused by the drug
- Advise patients to exercise caution when driving or operating machinery, as the drug may produce drowsiness, dizziness or blurred vision
Anturol, Oxytrol interacts with :
Pregnancy Category:B
Breastfeeding: Safety unknown. Data unavailable on the use of oxybutynin during breastfeeding. Prolonged use of oxybutynin may reduce milk production or milk letdown, but a single dose is unlikely to interfere with breastfeeding. During prolonged use, observe for signs of decreased lactation such as insatiety, poor weight gain. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 18 January 2011). Unknown whether excreted in human milk. Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Oxytrol 3.9 MG/24HR PTTW [Box] (WATSON LABS)
8 24hr = $250.8
24 24hr = $731.48
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
